Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Here is the third and final case I discussed with two great experts in locally advanced NSCLC. Drs. George Blumenschein, medical oncologist from MD Anderson Cancer Center in Houston, and Wally Curran, radiation oncologist from Winship Cancer Center at Emory University in Atlanta, joined me several weeks ago to discuss a series of challenging cases that illustrate the complexities and array of options in treating patients with stage III NSCLC.
This case is a woman with bulky stage IIIB NSCLC that involves lymph nodes above the collarbone (supraclavicular lymph nodes) on both sides, putting her in the outer reaches of what we could envision being treated for cure. Our discussion includes consideration of the potential approaches, including the potential value of chemo before or after concurrent chemo and radiation. It also covers the difficulty of assessing response after treatment, and the risk of radiation pneumonitis.
case-round-table-bulky-stage-iiib-nsclc-drs-blumenschein-and-curran-audio-podcast
case-round-table-bulky-stage-iiib-nsclc-drs-blumenschein-and-curran-figures
case-round-table-bulky-stage-iiib-nsclc-drs-blumenschein-and-curran-transcript
This program was made possible by a grant from OSI Pharmaceuticals. We are grateful for their support.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…